当前位置: 首页 >> 检索结果
共有 4246 条符合本次的查询结果, 用时 3.9020487 秒

2641. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

作者: Abhishek Abhishek.;Nicholas Peckham.;Corinna Pade.;Joseph M Gibbons.;Lucy Cureton.;Anne Francis.;Vicki Barber.;Jennifer A E Williams.;Duncan Appelbe.;Lucy Eldridge.;Patrick Julier.;Daniel M Altmann.;James Bluett.;Tim Brooks.;Laura C Coates.;Ines Rombach.;Amanda Semper.;Ashley Otter.;Ana M Valdes.;Jonathan S Nguyen-Van-Tam.;Hywel C Williams.;Rosemary J Boyton.;Áine McKnight.;Jonathan A Cook.; .
来源: Lancet Rheumatol. 2024年6卷2期e92-e104页
Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody response against the S1 receptor binding domain (S1-RBD) of the SARS-CoV-2 spike protein and live SARS-CoV-2 neutralisation compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases.

2642. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial.

作者: Anna Redl.;Konstantin Doberer.;Luisa Unterluggauer.;Lisa Kleissl.;Christoph Krall.;Carolina Mayerhofer.;Bärbel Reininger.;Victoria Stary.;Nina Zila.;Wolfgang Weninger.;Thomas Weichhart.;Christoph Bock.;Thomas Krausgruber.;Georg Stary.
来源: Lancet Rheumatol. 2024年6卷2期e81-e91页
Sarcoidosis is an inflammatory condition that can affect various organs and tissues, causing the formation of granulomas and subsequent functional impairment. The origin of sarcoidosis remains unknown and there are few treatment options. Mechanistic target of rapamycin (mTOR) activation is commonly seen in granulomas of patients across different tissues and has been shown to induce sarcoidosis-like granulomas in a mouse model. This study aimed to examine the efficacy and safety of the mTOR inhibitor sirolimus as a treatment for cutaneous sarcoidosis.

2643. Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study.

作者: Leticia Garcia-Montoya.;Jing Kang.;Laurence Duquenne.;Andrea Di Matteo.;Jacqueline L Nam.;Kate Harnden.;Rahaymin Chowdhury.;Kulveer Mankia.;Paul Emery.
来源: Lancet Rheumatol. 2024年6卷2期e72-e80页
Subclinical synovitis occurs in a third of individuals at risk of rheumatoid arthritis. The objective of this study was to assess the reversibility of subclinical synovitis in individuals at risk of rheumatoid arthritis who are positive for anti-cyclic citrullinated peptide (CCP) antibody with musculoskeletal symptoms and investigate factors associated with its resolution within 12 months.

2644. Association of economic insecurities with patient-reported outcomes in systemic lupus erythematosus.

作者: Ana Valle.;Candace H Feldman.
来源: Lancet Rheumatol. 2024年6卷2期e68-e70页

2645. Improving COVID-19 vaccine response in individuals receiving methotrexate.

作者: Katie Bechman.;James Galloway.
来源: Lancet Rheumatol. 2024年6卷2期e67-e68页

2646. Targeting mTOR in sarcoid granulomas: where the rubber meets the road.

作者: Adam S Morgenthau.
来源: Lancet Rheumatol. 2024年6卷2期e65-e66页

2647. Subclinical synovitis: let's discuss prognosis before treatment.

作者: Melek Yalcin-Mutlu.;Koray Tascilar.
来源: Lancet Rheumatol. 2024年6卷2期e64-e65页

2648. Pandemic to endemic: optimising COVID-19 immunity.

作者: The Lancet Rheumatology.
来源: Lancet Rheumatol. 2024年6卷2期e63页

2649. Cardiac myxoma mimicking a spondyloarthritis flare.

作者: Anastasia Delmotte.;Phalla Ou.;Ilyass Zouhry.;Patrick Nataf.;Philippe Dieudé.
来源: Lancet Rheumatol. 2024年6卷2期e128页

2650. Idiopathic inflammatory myopathies: current insights and future frontiers.

作者: Caoilfhionn M Connolly.;Latika Gupta.;Manabu Fujimoto.;Pedro M Machado.;Julie J Paik.
来源: Lancet Rheumatol. 2024年6卷2期e115-e127页
Idiopathic inflammatory myopathies are a group of autoimmune diseases with a broad spectrum of clinical presentations, primarily characterised by immune-mediated muscle injury. Until recently, there was little insight into the pathogenesis of idiopathic inflammatory myopathies, which challenged the recognition of the breadth of heterogeneity of this group of diseases as well as the development of new therapeutics. However, the landscape of idiopathic inflammatory myopathies is evolving. In the past decade, advances in diagnostic tools have facilitated an enhanced understanding of the underlying disease mechanisms in idiopathic inflammatory myopathies, enabling the expansion of therapeutic trials. The fields of transcriptomics, prot§eomics, and machine learning offer the potential to gain greater insights into the underlying pathophysiology of idiopathic inflammatory myopathies. Harnessing insights gained from these sophisticated tools could contribute to the identification of differences at a molecular level among patients, accelerating the development of targeted, tailored therapies. Bolstered by the validation and standardisation of robust outcome measures, many promising therapies are in clinical trial development. Although challenges remain, there is great optimism in the field due to the progress in innovative diagnostics, outcome measures, and therapeutic approaches. In this Review, we discuss the expanding landscape of idiopathic inflammatory myopathies as the frontier of precision medicine becomes imminent.

2651. Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study.

作者: Donavon Sandoval-Heglund.;Eric Roberts.;Joonsuk Park.;Maria Dall'Era.;Cristina Lanata.;Kamil E Barbour.;Kurt J Greenlund.;Caroline Gordon.;Patricia P Katz.;Jinoos Yazdany.
来源: Lancet Rheumatol. 2024年6卷2期e105-e114页
Social determinants of health are consistently associated with systemic lupus erythematosus (SLE) outcomes. However, social determinants of health are typically measured with conventional socioeconomic status factors such as income or education. We assessed the association of economic insecurities (ie, food, housing, health care, and financial insecurity) with patient-reported outcomes in a cohort of patients with SLE.

2652. Musculoskeletal magnetic resonance imaging findings support a common spectrum of giant cell arteritis and polymyalgia rheumatica.

作者: Pascal Seitz.;Jennifer Cullmann.;Susana Bucher.;Lukas Bütikofer.;Stephan Reichenbach.;Fabian Lötscher.;Jennifer Amsler.;Lisa Christ.;Harald M Bonel.;Peter M Villiger.;Luca Seitz.
来源: Rheumatology (Oxford). 2025年64卷1期321-331页
To investigate the proportion and distribution of contrast enhancement (CE) of musculoskeletal structures with MRI of the thorax/abdomen/pelvis in giant cell arteritis (GCA).

2653. Immune tolerance of citrullinated peptides.

作者: Ranjeny Thomas.;William H Robinson.
来源: Nat Rev Rheumatol. 2024年20卷3期141-142页

2654. Comment on: The risk of major adverse cardiovascular events in patients with systemic sclerosis: a nationwide, population-based cohort study.

作者: Fang-Yu Chen.;An-Ping Huo.;James Cheng-Chung Wei.
来源: Rheumatology (Oxford). 2024年63卷8期e236页

2655. Towards early diagnosis of axial psoriatic arthritis.

作者: Abdulla Watad.;Dennis McGonagle.
来源: Rheumatology (Oxford). 2024年63卷8期2042-2043页

2656. Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?

作者: Sarah J H Khidir.;Doortje I Krijbolder.;Herman K Glas.;Elise van Mulligen.;Annette H M van der Helm-van Mil.
来源: Rheumatology (Oxford). 2024年63卷9期2336-2344页
ACPA-positive and ACPA-negative RA differ in underlying risk factors but have a similar clinical presentation at RA diagnosis. It is unknown what the ACPA-associated differences or similarities are during the symptomatic at-risk stage of RA, i.e. clinically suspect arthralgia (CSA). To deepen insights into these differences/similarities, we compared the course of symptoms/impairments and subclinical joint inflammation in the CSA phase during progression to inflammatory arthritis (IA) or to CSA resolution.

2657. Transient palindromic rheumatism induced by chimeric antigen receptor T-cell therapy.

作者: José A Gómez-Puerta.;Andrés Ponce.;Ana Triguero.;Carlos Fernández de Larrea.;Raimon Sanmartí.
来源: Rheumatology (Oxford). 2024年63卷8期e215-e216页

2658. Correlation between the oxygenation status of extrasynovial tissue in the wrist and disease activity in rheumatoid arthritis: a photoacoustic imaging study.

作者: Zhibin Huang.;Huaiyu Wu.;Xiaoping Hong.;Di Song.;Weiyu Liang.;Qin Huang.;Xia Ye.;Wenyi Xu.;Qiu Hu.;Cuilian Liu.;Guoqiu Li.;Jinfeng Xu.;Fajin Dong.
来源: Rheumatology (Oxford). 2025年64卷2期493-500页
RA is characterized by hypoxia in the synovial tissue. While photoacoustic (PA) imaging offers a method for evaluating tissue oxygenation in RA patients, studies exploring the link between the oxygenation status of extrasynovial tissue in the wrist and disease activity remain scarce. We aimed to assess synovial oxygenation in RA patients using a multimodal photoacoustic-US (PA/US) imaging system and establish its correlation with disease activity.

2659. Biosimilar tocilizumab-better access and lower cost?

作者: Guro L Goll.;Tore K Kvien.
来源: Lancet Rheumatol. 2024年6卷1期e6-e8页

2660. Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

作者: Miriam F Cox.;Strachan Mackenzie.;Ryan Low.;Michael Brown.;Emilie Sanchez.;Aisling Carr.;Ben Carpenter.;Mark Bishton.;Andrew Duncombe.;Akpabio Akpabio.;Austin Kulasekararaj.;Fang En Sin.;Alexis Jones.;Akhila Kavirayani.;Ethan S Sen.;Vanessa Quick.;Gurdeep S Dulay.;Sam Clark.;Kris Bauchmuller.;Rachel S Tattersall.;Jessica J Manson.; .
来源: Lancet Rheumatol. 2024年6卷1期e51-e62页
Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any acutely unwell patient not responding to treatment as expected, with prompt assessment to look for what we term the three Fs-fever, falling blood counts, and raised ferritin. Worldwide, awareness of HLH and access to expert management remain inequitable. Terminology is not standardised, classification criteria are validated in specific patient groups only, and some guidelines rely on specialised and somewhat inaccessible tests. The consensus guideline described in this Health Policy was produced by a self-nominated working group from the UK network Hyperinflammation and HLH Across Speciality Collaboration (HiHASC), a multidisciplinary group of clinicians experienced in managing people with HLH. Combining literature review and experience gained from looking after patients with HLH, it provides a practical, structured approach for all health-care teams managing adult (>16 years) patients with possible HLH. The focus is on early recognition and diagnosis of HLH and parallel identification of the underlying cause. To ensure wide applicability, the use of inexpensive, readily available tests is prioritised, but the role of specialist investigations and their interpretation is also addressed.
共有 4246 条符合本次的查询结果, 用时 3.9020487 秒